title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Results | PMC10085031 | |||
Memorizing repetitions | The number of repetitions needed for memorizing the correct information in the LOW and HIGH conditions were 1.32 ( | PMC10085031 | ||
Outliers | The numbers of omitted outliers were 1.9 ( | PMC10085031 | ||
Hindsight bias index | An unpaired | PMC10085031 | ||
Percentage of hindsight bias index. | The hindsight bias index (%) was defined as 100 (initial responses-recollection values) / (initial responses—correct information), in which initial responses = numerical value of the initial responses, recollection values = numerical value of the recollection values, and correct information = numerical value of the cor... | PMC10085031 | ||
Ratio of items showing memory distortions | An unpaired | PMC10085031 | ||
The percentage of distorted items. | The distorted items (%) were calculated as the distorted items divided by all the items. “Total,” “Toward” and “Reversed” in the figure indicates the total percentage of distortions, the percentage of distorted items for correct information, and the percentage of distorted items against correct information, respectivel... | PMC10085031 | ||
Discussion | non-delayed recollections | The main finding of this study was that the MLOIE (i.e., the number of items to be remembered) affects the magnitude of hindsight bias, which supports the study’s tentative hypothesis. The larger the number of things to remember, the higher the hindsight bias. This finding is a simple but first reported contribution to... | PMC10085031 | |
Conclusions | In conclusion, the present study found that the memory load of information encoded (MLOIE) would amplify the magnitude of hindsight bias. The biased recollection degree was higher in the HIGH than the LOW condition, indicating that the memory load amplifies the magnitude of hindsight bias. This suggests that hindsight ... | PMC10085031 | ||
Supporting information | PMC10085031 | |||
English Hindsight Bias Test (HBT) items. | (DOCX)Click here for additional data file. | PMC10085031 | ||
Japanese Hindsight Bias Test (HBT) items. | (DOCX)Click here for additional data file. | PMC10085031 | ||
Original data of the hindsight bias index. | (XLSX)Click here for additional data file. | PMC10085031 | ||
References | PMC10085031 | |||
Background | HAND INFECTION | Although airway management for paramedics has moved away from endotracheal intubation towards extraglottic airway devices in recent years, in the context of COVID-19, endotracheal intubation has seen a revival. Endotracheal intubation has been recommended again under the assumption that it provides better protection ag... | PMC10184619 | |
Methods | shockable, VF, non-shockable | SECONDARY | In this manikin study paramedics performed advanced cardiac life support with non-shockable (Non-VF) and shockable rhythms (VF) in four settings: ERC guidelines 2021 (control), COVID-19-guidelines using videolaryngoscopic intubation (COVID-19-intubation), laryngeal mask (COVID-19-Laryngeal-Mask) or a modified laryngeal... | PMC10184619 |
Results | A total of 120 resuscitation scenarios were completed. Compared to control (Non-VF:11 ± 3 s, VF:12 ± 3 s) application of COVID-19-adapted guidelines lead to prolonged no-flow times in all groups (COVID-19-Intubation: Non-VF:17 ± 11 s, VF:19 ± 5 s;p ≤ 0.001; COVID-19-laryngeal-mask: VF:15 ± 5 s,p ≤ 0.01; COVID-19-shower... | PMC10184619 | ||
Conclusions | COVID-19-adapted guidelines using videolaryngoscopic intubation lead to a prolongation of no-flow time. The use of a modified laryngeal mask with a shower cap seems to be a suitable compromise combining minimal impact on no-flowtime and reduced aerosol exposure for the involved providers. | PMC10184619 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12873-023-00820-y. | PMC10184619 | ||
Keywords | Open Access funding enabled and organized by Projekt DEAL. | PMC10184619 | ||
Background | infection | INFECTION | Based on experience with SARS-CoV-1, the resuscitation guidelines were adapted to mitigate the risk of infection for the rescuers, while accepting an increase in no-flow time and possibly worse patient outcomes [ | PMC10184619 |
Methods | shockable, OHCA | Ethical approval for this study (Ethical Committee No 2021-414-f-S) was granted on July, 2th 2021 by the Ethical Committee of the University Hospital of Muenster, Muenster, Germany (Chairperson Prof W.E. Berdel). The study was performed at a training center for paramedics in Bielefeld, Germany in August 2021 (‘Studieni... | PMC10184619 | |
Analysis | SAID | STATA version 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.) was used for statistical analyses. The sample size was calculated with a standardized tolerance limit of one standard deviation and no difference, 20 participants were required for a power = 0.8 with a signif... | PMC10184619 | |
Discussion | infection, OHCA, vomiting, SAD | INFECTION, WASTED, COMPLICATIONS | The present paper compares no-flow time and established quality indicators of resuscitation as well as aerosol release using COVID-19 resuscitation guidelines including three different airway management strategies in accordance with the ERC-2021 using a simulation model [Over the last decade, the impact of different ai... | PMC10184619 |
Limitations | As the influence of the different airway devices on key performance indicators of resuscitation was investigated, the application of the PPE was not part of the study, but obviously leads to a further prolongation of no-flow time [ | PMC10184619 | ||
Conclusions | The present study shows that the COVID-19-adapted guidelines using ETI led to a prolongation of the no-flow time, which markedly worsened the overall quality of resuscitation. These effects can be attenuated using an SAD. Although the influence of airway management on the outcome of resuscitation and the transmission o... | PMC10184619 | ||
Acknowledgements | The authors would like to thank Marvin Deslandes for revision and Helge Myklebust and Laerdal Medical for kindly providing the ’Shower-cap’ concept. | PMC10184619 | ||
Authors’ contributions | TB | SSS has been involved in acquisition of data, drafting the manuscript, revising it critically for important intellectual content, gave final approval of the version to be published and gave the Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any... | PMC10184619 | |
Funding | No funding was obtained for this study.Open Access funding enabled and organized by Projekt DEAL. | PMC10184619 | ||
Data Availability | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10184619 | ||
Declarations | PMC10184619 | |||
Ethics approval and consent to participate | Ethical approval for this study (Ethical Committee No 2021-414-f-S) was granted on July, 2th 2021 by the Ethical Committee of the University Hospital of Muenster, Muenster, Germany (Chairperson Prof W.E. Berdel). All methods were carried out in accordance with relevant guidelines and regulations in Ethics declaration s... | PMC10184619 | ||
Consent for publication | Not applicable. | PMC10184619 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10184619 | ||
Abbreviations | StatesVentricular Fibrillation, Respiratory Syndrome | Basic Life-SupportCardiopulmonary ResuscitationCorona-Virus-Disease 2019Endotracheal IntubationEuropean Resuscitation Council 2021Extraglottic Airway DevicesFiltering Face Piece 3Laryngeal Mask AirwayOut-of-Hospital Cardiac ArrestPersonal Protective EquipmentSevere Acute Respiratory Syndrome Corona-Virus 1United States... | PMC10184619 | |
References | PMC10184619 | |||
Background | prostate cancer, Prostate | DISEASE, PROSTATE CANCER, PROSTATE | Isolated local failure (ILF) can occur in patients who initially receive definitive radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) brachytherapy. Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) can accurately detect ILF and can exclude extrapros... | PMC10116658 |
Methods | toxicity, prostate cancer | DNA DAMAGE, PROSTATE CANCER, PROSTATE | ROADSTER is a phase I/II randomized, single-institution study. Patients with an ILF of prostate cancer after definitive initial radiation therapy are eligible. The ILF will be confirmed with biopsy, magnetic resonance imaging (MRI) and PSMA PET. Patients will be randomized between HDR brachytherapy in two fractions (a ... | PMC10116658 |
Discussion | ROADSTER explores a novel salvage therapy for ILF after primary radiotherapy with combined Lutetium-177 PSMA RLT and HDR brachytherapy. The randomized phase I/II design will provide a contemporaneous patient population treated with HDR alone to facilitate assessment of feasibility, tolerability, and biologic effects of... | PMC10116658 | ||
Trial registration | NCT05230251 (ClinicalTrials.gov). | PMC10116658 | ||
Keywords | PMC10116658 | |||
Background | toxicity, prostate, Prostate cancer, prostate cancer deaths, prostate cancer | DISEASE, PROSTATE CANCER RECURRENT, DNA DAMAGE, PROSTATE, PROSTATE CANCER, PROSTATE CANCER | Prostate cancer is a major male health issue, with over 1.4 million new cases of prostate cancer diagnosed and 375,000 new prostate cancer deaths in 2020 worldwide [There are several potentially curative treatment options for patients with ILF, including salvage radical prostatectomy (RP), as well as prostate directed ... | PMC10116658 |
Methods | PMC10116658 | |||
Inclusion and exclusion criteria | prostate cancer, prostate | PROSTATE CANCER, PROSTATE, PROSTATIC DISEASE | Patients with suspected ILF after radiation will be recruited. Patients must have a BCF per Phoenix criteria at least two years after initial prostate cancer treatment, an intra-prostatic lesion with PSMA PET avidity (Standard Uptake Value (SUV) of 3.0 or greater on a diagnostic PSMA PET/CT), and no evidence of extra p... | PMC10116658 |
Baseline assessment | toxicity, D.L., Prostate Cancer, prostate cancer | PROSTATE CANCER, PROSTATE CANCER | Patients will be required to complete baseline assessments of toxicity by CTCAE v4.0, quality of life (QoL) related to prostate cancer by the Expanded Prostate Cancer Index Composite (EPIC), and baseline bloodwork to assess marrow, renal and hepatic function. Baseline bloodwork and urine samples will be collected as li... | PMC10116658 |
Treatment | tumor, CTVp | PRIMARY TUMOR, TUMOR, PROSTATE, DISEASE | The trial schema is given in Fig.
ROADSTER trial schemaBrachytherapy will be performed using transrectal ultrasound (TRUS) guidance, under general anesthesia in a dedicated brachytherapy suite, with intraoperative planning. Pre-procedure PSMA PET/MR images will be fused with intra-operative TRUS images using an in-hou... | PMC10116658 |
Primary and secondary endpoints | toxicity | SECONDARY | ROADSTER is a phase I/II, randomized controlled trial with safety and feasibility as primary outcomes. The planned accrual for the phase I portion of the study will be 12 patients: six patients in cohort 1 and six patients in cohort 2. Safety of each cohort will be declared if no more than one patient in each cohort ex... | PMC10116658 |
Translational exploratory endpoints | toxicity, tumor, prostate cancer, prostate | TUMOR, DNA DAMAGE, PROSTATE, BLOOD, PROSTATE CANCER | At the time of the second HDR treatment for cohort 1 and the HDR treatment for cohort 2, patients will receive a research prostate biopsy via a transperineal approach under ultrasound guidance. Targeted biopsies of PSMA PET/MR defined lesions will be obtained along with systematic biopsies of the whole gland. These tis... | PMC10116658 |
Discussion | tumor, CRPC, occult extra-prostatic disease, toxicity, occult metastatic disease, prostate, prostate HDR, prostate cancer | TUMOR, DISEASE, RECURRENT DISEASE, METASTATIC DISEASE, PROSTATE, SECONDARY, PROSTATE CANCER, CANCER RELAPSE | As a primary outcome, the ROASDTER trial investigates the feasibility and safety of a novel salvage strategy that combines Lu-177 PSMA RLT with HDR brachytherapy in patients with proven radiorecurrent ILF with no signs of metastatic disease. By adding Lu-177 PSMA RLT as a systemic therapy early in the course of cancer ... | PMC10116658 |
Acknowledgements | The authors acknowledge the patients who enrolled in this trial and supported this research. | PMC10116658 | ||
Authors’ contributions | LCM | AD – Wrote initial draft of manuscript and approved finalized manuscript. GB – Trial concept development and protocol writing. Edited initial draft of manuscript and approved finalized manuscript. LCM – Trial concept development and protocol writing. Edited initial draft of manuscript and approved finalized manuscript.... | PMC10116658 | |
Funding | This trial was funded with support from the London Health Sciences Foundation. The London Health Sciences Foundation did not contribute to the study design; the collection, management, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication. | PMC10116658 | ||
Data Availability | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10116658 | ||
Declarations | PMC10116658 | |||
Competing interests | CCSRI, CRS, MM | LCM | AD – none. GB – Industry Advisory Boards and Speaking – Tolmar, Trelstar, and Advanced Accelerator Applications; Industry Research – Siemens, and Invicro; Leadership – OICR Clinical Lead Clinical Translation Program, and OH-CCO PET Steering Committee; Research Funding – OICR, CIHR, and CCSRI. LCM – none. DL – none. MM ... | PMC10116658 |
Ethics approval and consent to participate | This study has been approved by the Western University Health Sciences Research Ethics Board (Project ID: 120132) and will be conducted in accordance with the principles of the Declaration of Helsinki. Western University, located in London, Ontario, Canada, is the University partner of the London Health Sciences Centre... | PMC10116658 | ||
Consent to publish | Patients will give their consent voluntarily to have the results published. | PMC10116658 | ||
References | PMC10116658 | |||
Subject terms | VF, glaucoma, Retinal nerve fiber layer | GLAUCOMA SUSPECT, GLAUCOMA | This study compared between TEMPO, a new binocular perimeter, with the Humphrey Field Analyzer (HFA). Patients were tested with both TEMPO 24–2 Ambient Interactive Zippy Estimated by Sequential Testing (AIZE)-Rapid and HFA 24–2 Swedish Interactive Threshold Algorithm (SITA)-Fast in a randomized sequence on the same day... | PMC10692178 |
Introduction | fatigue, optic neuropathy, Glaucoma | OPTIC NEUROPATHY, GLAUCOMA | Glaucoma is an optic neuropathy characterized by the gradual loss of retinal ganglion cells and their axons, which can lead to vision lossWe hypothesized that this new technology could reduce testing duration and patient fatigue, minimize variability in test results, and improve the correlation between structural and f... | PMC10692178 |
Discussion | VF, strabismus, nystagmus, glaucoma, TEMPO | DISEASE, STRABISMUS, NYSTAGMUS, DYSFUNCTION, GLAUCOMA, ANISOMETROPIA | In this study, we prospectively performed VF testing with both TEMPO AIZE-Rapid and HFA Swedish Interactive Threshold Algorithm (SITA)-Fast in a randomized order and identified a stronger structure–function relationship and better reliability indices with TEMPO compared to HFA. TEMPO reduced measurement time by approxi... | PMC10692178 |
Methods | PMC10692178 | |||
Participants | Glaucomatous optic neuropathy, glaucomatous VF damage, glaucomatous optic neuropathy, glaucomatous defect, atrophy, glaucoma, Glaucoma | GLAUCOMATOUS OPTIC NEUROPATHY, INTRAOCULAR PRESSURE, PRIMARY ANGLE CLOSURE GLAUCOMA, GLAUCOMA SUSPECT, PRIMARY OPEN-ANGLE GLAUCOMA, ATROPHY, SECONDARY GLAUCOMA, GLAUCOMA, AGE-RELATED MACULAR DEGENERATION, EYE, GLAUCOMA, GLAUCOMA SUSPECT | Participants were recruited from patients at the Shiley Eye Institute, University of California, San Diego. The research protocol followed the tenets of the Declaration of Helsinki and was approved by the University of California, San Diego Institutional Review Board. All study participants provided written informed co... | PMC10692178 |
Visual field testing | TEMPO (CREWT Medical Systems, Tokyo, Japan) is the commercial name of the product. It is distinct from the portable head-mounted perimeter device known as imoFor the current study, all patients underwent HFA 24–2 SITA-Fast and TEMPO 24–2 AIZE-Rapid on the same day in a randomized order using Goldmann size III (0.431° v... | PMC10692178 | ||
Structure–function relationship | VF, RA, retinal nerve fiber | RNFL was measured using Cirrus spectrum-domain OCT (Carl Zeiss Meditec, Inc, Dublin, CA) Optic Disc Cube 200 × 200 protocol scans. A 3.46 mm diameter circle was automatically placed around the optic disc, providing RNFL thickness globally and in superior, inferior, temporal, and nasal sectors. Coefficient of determinat... | PMC10692178 | |
Statistical analysis | VF | Patient and eye characteristics were reported as mean (95% CI) for continuous data and count (percentage) for categorical data. MD, PSD, foveal threshold (FT), and VFI were compared using mixed-effects model between the two perimeters. Reliability indices were illustrated in a kernel density estimate plot to compare th... | PMC10692178 | |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-48105-5. | PMC10692178 | ||
Acknowledgements | DISEASE, EYE | T.N.: C: Topcon (consultant). R.N.W.: Abbvie, Alcon, Allergan, Amydis, Editas, Eyenovia, Iantrek, IOPtic, Implandata, iSTAR Medical, Nicox, Santen, Tenpoint, and Topcon (consultant); National Eye Institute, National Institute for Minority Health and Health Disparities, Centervue (research support); Toromedes, Carl Zeis... | PMC10692178 | |
Author contributions | Designed and conducted the study: T.N., R.N.W. and S.M. Data collection: T.N. and J.A., Data analysis: T.N. Interpretation: T.N., R.N.W. and S.M. Writing: T.N. and R.N.W. Critical revision: All authors. Manuscript approval: All authors. | PMC10692178 | ||
Funding | EYE | Supported by R01EY029058 and R01EY034148 (RNW) from National Institutes of Health/National Eye Institute Grants. | PMC10692178 | |
Data availability | The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. | PMC10692178 | ||
Competing interests | The authors declare no competing interests. | PMC10692178 | ||
References | PMC10692178 | |||
Purpose | MPE | Communicated by Fabio fischetti.To compare fixed transverse textile electrodes (TTE) knitted into a sock versus motor point placed standard gel electrodes (MPE) on peak venous velocity (PVV) and discomfort, during calf neuromuscular electrical stimulation (calf-NMES). | PMC10460736 | |
Methods | NRS, MPE | Ten healthy participants received calf-NMES with increasing intensity until plantar flexion (measurement level I = ML I), and an additional mean 4 mA intensity (ML II), utilizing TTE and MPE. PVV was measured with Doppler ultrasound in the popliteal and femoral veins at baseline, ML I and II. Discomfort was assessed wi... | PMC10460736 | |
Results | MPE | TTE and MPE both induced significant increases in PVV from baseline to ML I and significantly higher increases to ML II, in both the popliteal and femoral veins (all | PMC10460736 | |
Conclusion | MPE | TTE integrated in a sock produces intensity-dependent increases of popliteal and femoral hemodynamics comparable to MPE, but results in more discomfort at plantar flexion due to higher current required. TTE exhibits in the popliteal vein higher increases of PVV compared to MPE. | PMC10460736 | |
Trial registration | Trial_ID: ISRCTN49260430. Date: 11/01/2022. Retrospectively registered. | PMC10460736 | ||
Keywords | Open access funding provided by Karolinska Institute. | PMC10460736 | ||
Introduction | fits, MPE, venous stasis, VTE, Venous stasis, venous thromboembolism | SECONDARY, VENOUS STASIS, DEEP VEIN THROMBOSIS (DVT), VENOUS STASIS | Venous stasis is one of the major causes of venous thromboembolism (VTE), which often starts as a deep vein thrombosis (DVT). VTE-prevention targeting venous stasis of the calf include passive compression socks and active mechanical interventions, such as intermittent pneumatic compression and neuromuscular electrical ... | PMC10460736 |
Materials and methods | PMC10460736 | |||
Electrode-setups | MP, MPE | In this study, two different electrode setups for applying NMES to the calf were tested and compared regarding various outcomes. The electrode setups differed regarding electrode- type, and placement and were compared to investigate if textile electrodes knitted in fixed transverse positions in a sock, would yield a no... | PMC10460736 | |
Motor point scan | MP | The best MPs were found by scanning one half of the calf at a time (medial/lateral), using the NMES device’s 3 Hz sinusoidal wave motor scan program (Chattanooga Physio constant current generator, DJO Nordic, Malmoe, Sweden). Prior to the MP scan, the side of the calf about to be scanned was covered by a thin layer of ... | PMC10460736 | |
NMES-Settings | MP | For both electrode setups, NMES was applied using the same NMES device as for the MP scan. The NMES stimulation used a biphasic symmetric square wave, meaning that the electrodes continuously were switching polarity so that they alternately, and for equally long durations, served as either anode or cathode. Thus, there... | PMC10460736 | |
NMES Measurement Level I & II | The NMES-device display the current used for the selected stimulation in NMES-levels ranging from 0 to 999, which in a non-linear pulse duration dependent fashion correlate to current amplitudes ranging from 0 to 120 mA. The formula to calculate this correlation may be obtained from the manufacturer (DJO Nordic, Malmoe... | PMC10460736 | ||
Hemodynamic measurements | CONTRACTION | Using a Philips CX50 (2013) Doppler ultrasound machine (Philips Medical Systems, Andover, MA, USA), the widest accessible part of the popliteal and femoral veins was located and visualized in a longitudinal plane before beginning the hemodynamic measurements. The diameters of the veins were calculated at baseline. The ... | PMC10460736 | |
Discomfort | NRS | For each stepwise increase in NMES-levels when testing the two electrode setups, participants were asked to fill in a form to rate their discomfort on a numerical rating scale (NRS) 0–10, where 0 was described to the subject as no discomfort and 10 as the worst imaginable discomfort (Hawker et al. | PMC10460736 | |
Statistical analysis | NRS | The sample size was determined prior to the start of the experiment based on a pilot study with a difference in PPV between ML I to ML II of 20 cm/s and sigma of 20, with the significance level set at The data were analyzed using SPSS version 27 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Armonk, NY: IBM... | PMC10460736 | |
Results | PMC10460736 | |||
Current intensities in mA for calf-NMES | MPE | The median (IQR) current intensity required to reach ML I, was significantly lower when using MPE, 16 (7.4) mA, as compared to TTE, 26 (14) mA (Current intensity (mA) required to reach ML I displayed for the TTE and MPE setups. In the boxplot, the length of the box represents IQR, and error bars represent min–max. The ... | PMC10460736 | |
Hemodynamics of calf-NMES | PMC10460736 | |||
Hemodynamics in the popliteal vein | MPE | The median (IQR) baseline PVV in the popliteal vein was 14.3 (5.4) cm/s. There were significant increases of PVV from baseline to ML I when using both TTE, 29.1 (47.3) cm/s (Hemodynamics in the popliteal vein. Percentual increase of PVV from baseline to ML I and ML II displayed for the TTE and MPE setups. In the boxplo... | PMC10460736 | |
Hemodynamics in the femoral vein | MPE | The median (IQR) baseline PVV in the femoral vein was 14.2 (3.9) cm/s. PVV exhibited statistically significant increases from baseline to ML I when using both TTE, 21.6 (8.8) cm/s (Hemodynamics in the femoral vein. Percentual increase of PVV from baseline to ML I and ML II for the TTE and MPE setups. In the boxplot, th... | PMC10460736 | |
Discomfort of calf NMES | NRS, MPE | Using MPE resulted in a statistically significantly lower median NRS (range), 1 (0–3), compared to the use of TTE, NRS 2 (0–7), at ML I (Discomfort of calf NMES. NRS score for the TTE and MPE setups at ML I and ML II. In the boxplot, the length of the box represents IQR, and error bars represent min–max and in case of ... | PMC10460736 | |
Associations of participant characteristics with outcome | MPE | Female participants, as compared to male participants, required significantly higher current intensity (mA) to produce a plantar flexion, both with TTE and MPE ( | PMC10460736 | |
Discussion | Uhl, pelvic fractures, MPE, venous stasis, DVT, VTE, MP | BLOOD CLOTS, EVANS, VENOUS STASIS, DVT | The main finding of this study was that the PVV in both the popliteal and the femoral veins exhibited a dose–response relationship to the current intensity administered to the calf, for both the TTE and the MPE setups. The TTE setup required higher current intensity than the MPE setup to induce a plantar flexion (ML I)... | PMC10460736 |
Conclusion | NMES of the calf increases PVV in an intensity-dependent and clinically relevant manner in both the popliteal and femoral veins using both a TTE | PMC10460736 | ||
Acknowledgements | Not applicable. | PMC10460736 | ||
Author contributions | PA, JF and RJ wrote the application for the approved ethical permit. RJ, PA, JF, LG, N-KP and CS performed material preparation and created the study protocol. CS and RJ collected and prepared the data for statistical analysis. CS performed the statistical analysis. CS, RJ, JF, and PA wrote the manuscript. All authors ... | PMC10460736 | ||
Funding | Open access funding provided by Karolinska Institute. This work was supported by the strategic innovation programs Swelife and Medtech4Health, which are jointly arranged and funded by Sweden´s Innovation Agency (Vinnova), Grant no: 2019-05479 Formas and Energimyndigheten. | PMC10460736 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.